ABOUT US OUR FOCUS OUR PRODUCTS SCIENCE FUNDING PROGRAMS NEWSROOM INVESTORS Advancing the Science “We see pitolisant as a portfolio in a product opportunity and are taking a mechanism-based approach to future clinical development. Our goal is to utilize pitolisant’s unique mechanism of action to address unmet medical needs for people living with rare neurological diseases.” Jeffrey Dayno, M.D., Chief Medical Officer ABOUT PITOLISANT Pitolisant was designed and developed by Bioprojet Societe Civile de Recherche (Bioprojet), which has marketed the product in Europe since its approval by the European Medicines Agency in 2016. Harmony has an exclusive license from Bioprojet to develop, manufacture, and commercialize pitolisant in the United States. ABOUT HBS-102 HBS-102, an investigational compound, is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that has the potential to offer a novel approach to the treatment of a variety of rare neurological diseases. Melanin-concentrating hormone neurons are located in the hypothalamus and are involved in several different functions, including feeding behaviors, energy balance and control of metabolic functions, rapid eye movement (REM) sleep, mood and behavioral processing, among others. OUR PIPELINE The company is currently evaluating the novel mechanism of action of pitolisant for broader applications in neurological diseases that may be mediated by the H3 receptor. This mechanism-based approach for pitolisant offers the potential for future clinical development in a variety of conditions beyond disorders of wakefulness. We are evaluating the potential of HBS-102, an early-stage asset with a novel mechanism of action, for a variety of indications in patient populations living with rare neurological diseases. PIPELINE CHART For more information about Harmony’s ongoing clinical trials, please visit NCT04257929 (Prader-Willi Syndrome) or NCT04886518 (Myotonic Dystrophy). Harmony Biosciences 630 W. Germantown Pike, Suite 215 Plymouth Meeting, PA 19462 HarmonyBiosciences.com Harmony Biosciences name and logo are registered trademarks. ©2021 Harmony Biosciences. All Rights Reserved. US-HAR-2100055/Oct 2021 ABOUT US LEADERSHIP CULTURE ETHICS/COMPLIANCE FUNDING PROGRAMS CONTACT US PRIVACY POLICY TERMS OF USE OUR FOCUS ABOUT NARCOLEPSY SCIENCE ADVANCING THE SCIENCE SAFETY DATA SHEET NEWSROOM PRESS RELEASES INVESTORS SOCIAL MEDIA LINKEDIN TWITTER COMMUNITY GUIDELINES SITEMAP By continuing to browse this website, you are agreeing to accept our use of cookies, To learn more about our Privacy policy, click here. X